preliminary phase i/iia trial results

SOLBEC PRELIMINARY PHASE I/IIA TRIAL RESULTS

Perth, Australia. 29 March 2005. Solbec Pharmaceuticals Ltd (ASX:SBP) announced today
the preliminary results of its phase I/IIA trial designed to assess the safety and tolerability of
its compound Coramsine™ as a topical treatment for Psoriasis.
Solbec is pleased to announce that the trial has shown that Coramsine™ 0.01% cream can be
used on psoriasis patients safely and was well tolerated.
The trial showed varied effective activity with Coramsine 0.01% cream amongst the trial
patients however, in its present formulation, the cream was not assessed to be more effective
than the control cream in relieving symptoms of psoriasis. Additional formulation work will
be carried out to further enhance the composition of the Coramsine™ cream before
committing to larger Phase II developments.
The trial was designed as a safety and tolerability study and not designed to show sufficient
statistical power to determine whether Coramsine™ 0.01% cream was more effective than the
current standard treatment.
Further details of the trials will be released when to hand, with the full report from CMAX
being expected in about 6 weeks which will further detail the level of activity identified at this
early stage.
These preliminary results demonstrate the safety and tolerability of the current composition
and have identified activity.

Background Information
Solbec Pharmaceuticals
Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of better
therapies for debilitating conditions and life-threatening diseases. The company is currently progressing its key
project, Coramsine™, through Phase I/IIA clinical trials for the treatment of advanced solid tumours, and as a
topical treatment for psoriasis. Solbec's two proprietary ingredients in Coramsine™ were isolated from the fruit of
a weed known as the Devil’s Apple (Solanum linnaeanum). They show activity against some cancers and cause
potentially therapeutic changes to the immune system. In addition to human health, Coramsine™ has potential
application in the areas of animal health and diagnostics. Solbec’s business strategy is to partner or out-license
Coramsine™ for the final stages of pre-commercial development and marketing.
www.solbec.com.au